Inspiring Creator Builds Loyal Livestream Audience by Showing Exactly How He Breaks His Lifetime Pharma Ban

WASHINGTON — In what can only be described as one of the most authentic creator journeys of the decade, former pharmaceutical executive Martin Shkreli has spent the past four years building a devoted livestream audience around a bold, disruptive content format: trading drug-company stocks on camera while under a lifetime ban from the drug industry.

The Federal Trade Commission and the attorneys general of seven states on Tuesday asked a federal judge to hold Shkreli in contempt, saying he “flagrantly and repeatedly” violated the ban nearly the entire time it has existed. This reporter, a founder himself, prefers to call it “consistency,” which every growth coach agrees is the number one thing that builds an audience.

Shkreli’s origin story will be familiar to fans. He raised the price of Daraprim, a lifesaving anti-parasitic drug, from $17.50 a pill to $750 a pill virtually overnight, an increase of more than 4,000 percent, while blocking cheaper generic competitors from reaching the market. He separately served time on a seven-year sentence for securities fraud. In 2022 a federal court banned him from the pharmaceutical industry for life over the Daraprim scheme, writing that his “egregious, deliberate, repetitive, long-running, and ultimately dangerous illegal conduct” warranted it. The ban specifically prohibits him from owning pharmaceutical stock and from making public statements that could influence a pharmaceutical company’s business.

Most creators would see that as a limitation. Shkreli saw a content pillar.

According to the filing, his channel grew across four distinct eras, like any great franchise: a 2022 trading competition with another YouTuber, a 2024 short on a small biotech firm, a 2025 trading challenge in which he shorted three small biotech firms, and a fresh season launched in June 2026 with a $10 million account. In true build-in-public fashion, he sometimes showed his brokerage accounts right on screen.

His audience engagement numbers are, frankly, the envy of the industry. After he advised viewers last year to short one pharmaceutical company, that company’s stock quickly fell 17 percent, the kind of conversion rate this reporter’s water-reminder app has never once achieved.

He also shared his secret sauce with fans for free. “It doesn’t matter what trades I make because I can always find a couple of biotech stocks to smoke,” he told viewers in 2025, calling it his “magic trick.” Experts agree that giving away your best tips builds trust.

This reporter had to jump on a quick call at this point. He is back now.

The FTC says the stocks discussed on stream are “likely the tip of the iceberg,” since staff reviewed only a fraction of his social media activity. Shkreli himself has teased additional accounts, the filing says, in what this reporter recognizes as a classic premium-tier upsell. “I have some other accounts that I’[d] show you, but, like, I know feds are watching, so f[*]ck that,” he told his audience.

“Honestly, he’s the most transparent finance guy I watch,” said Dale Kroeger, 38, a Region resident and longtime subscriber who described himself as “mostly in it for the chat.” “He tells you exactly what he’s doing. He tells you exactly why he’s not allowed to do it. Then he does it. You don’t get that kind of honesty from the big banks.”

The FTC and the states want the court to make Shkreli sell all of his pharmaceutical holdings, pay a fine equal to his profits from trading them, and spell out “clear and escalating consequences” for any future violations, up to and including incarceration, a move this reporter worries could seriously hurt his upload schedule.

“A lifetime industry ban is only effective if breaches are met with consequences commensurate with the seriousness of the order,” FTC Commissioner Mark Meador said in a statement.

Shkreli responded on social media that he was surprised by the filing. “I could see totalitarian NY AG Letitia James trying to limit a citizen’s free speech but not from Trump’s FTC,” he wrote.

This reporter has reached out about a possible collab and is optimistic. He did not realize until just now that the ban was over a scheme to keep a lifesaving pill 4,000 percent more expensive, and is no longer sure the collab is a good idea.